Development and validation of an RP-HPLC-UV method for the determination of ondansetron in rabbit plasma: Application to a pharmacokinetic study

• Autorzy: Ravi S. , Khan N. , Darwis Y
• Języki publikacji: EN

Abstrakty

EN

A new sensitive and specific isocratic RP-HPLC-UV method was developed and validated for the determination of ondansetron in rabbit plasma using risperidone as an internal standard (IS). The sample preparation involved a simple deprotenization procedure with a mixture of 1 mL of acetonitrile and 50 μL of 10% w/υ zinc sulfate. Analysis was performed on a Phenomenex CN column (250 mm × 4.6 mm, 5 μm) with 50 mM ammonium acetate (pH 3.5) and acetonitrile (35:65, υ/υ) as mobile phase at a flow rate of 1.0 mL min^-1. Column eluent was monitored at 310 nm. The calibration curve was linear over the concentration range of 25–1000 ng mL^-1. (r² = 0.9999) with a limit of quantification (LOQ) 25 ng mL. ^-1.The intraday and interday precision and accuracy were between 0.93% and 3.41% and −3.63% and 1.01%, respectively. The mean recoveries of ondansetron and risperidone were 85.87% and 99.80%, respectively. Ondansetroncontaining plasma samples were stable at −20°C for 14 days. The validated method was successfully applied for a pharmacokinetic study after a single oral administration of ondansetron (8 mg) to rabbits.

Słowa kluczowe

EN

ondansetron; RP-HPLC-UV; method validation; rabbit plasma; pharmacokinetics

• Wydawca: University of Silesia in Katowice ; Akademiai Kiado
• Czasopismo: Acta Chromatographica
• Rocznik: 2011
• Tom: Vol. 23, no. 4
• Strony: 579--593
• Opis fizyczny: Bibliogr. 18 poz., rys., tab.

Twórcy

autor

Ravi S.

• University Sains Malaysia School of Pharmaceutical Sciences 11800 Penang Malaysia

autor

Khan N.

• University Sains Malaysia School of Pharmaceutical Sciences 11800 Penang Malaysia

autor

Darwis Y

• University Sains Malaysia School of Pharmaceutical Sciences 11800 Penang Malaysia

Bibliografia

• [1] Fabi, M. Ciccarese, G. Metro, A. Savarese, D. Giannarelli, C.M. Nuzzo, M. Russillo, I. Sperduti, I. Carbone, E. Bria, and F. Cognetti, Support. Care Cancer, 16, 1375 (2008)
• [2] S. Ravi, Y. Darwis, and N. Khan, Chromatographia, 70, 75 (2009)
• [3] M. Depot, S. Leroux, and G. Caille, J. Chromatogr. B, 693, 399 (1997)
• [4] S. Bauer, E. Stormer, R. Kaiser, P.B. Tremblay, J. Brockmoller, and I. Roots, Biomed. Chromatogr., 16, 187 (2002)
• [5] D. Chandrasekar, S. Ramakrishna, and P.V. Diwan, Arzneimittel-Forsch., 54, 655 (2004)
• [6] P.V. Colthup, C.C. Felgate, J.L. Palmer, and N.L. Scully, J. Pharm. Sci., 80, 868 (1991)
• [7] J.W. Kelly, L. He, and J.T. Stewart, J. Chromatogr., 622, 291 (1993)
• [8] J. Liu and J.T. Stewart, J. Chromatogr. B, 694, 179 (1997)
• [9] V. Sutariya and R. Mashru, AAPS Annual Meeting and Exposition (2006)
• [10] Y.P. Armando, S.G. Schramm, M.D.F. Silva, E.K. Kano, E.E.M. Koono, V. Porta, and C.H.D.R. Serra, Int. J. Pharm., 366, 149 (2009)
• [11] Y. Dotsikas, C. Kousoulos, G. Tsatsou, and Y.L. Loukas, J. Chromatogr. B, 836, 79 (2006)
• [12] K. Liu, X. Dai, D. Zhong, and X. Chen, J. Chromatogr. B, 864, 129 (2008)
• [13] X. Xu, M.G. Barlett, and J.T. Stewart, J. Mass Spectrom., 35, 1329 (2000)
• [14] USFDA, Guidance for Industry: Bioavailability and bioequivalence studies for orally administered drug products — General considerations. US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), Rockville, MD, March 2003
• [15] Note for Guidance: Investigation of Bioavailability and Bioequivalence. Committee for Proprietary Medicinal Products (CPMP), London, UK, December 2000
• [16] R.L. Nation and L.N. Sansom, Pharmacol. Therapeut., 62, 41 (1994)
• [17] J.G. Wagner, Statistics: Fundamentals of Clinical Pharmacokinetics, Drug Intelligence Publications, Hamilton, 1975, 285
• [18] USFDA, Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), Rockville, MD, May 2001